A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes

Key Inclusion Criteria (Part 1 and Part 2): * Diagnosis of MDS by bone marrow biopsy. * International Prognostic Scoring System (IPSS) score of low or intermediate-1 risk MDS. * May have received prior therapy for MDS. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2. * Adequate liver and renal function. * Additional criteria exist. Key Exclusion Criteria (Part 1 and Part 2): * History of bone marrow transplant. * Treatment for MDS other than transfusions or a stable dose (≥ 4 weeks) of hematopoietic growth factors on the day of the first dose of study drug. * Concomitant malignancies or previous malignancies with less than a 2-year disease-free interval at the time of enrollment. * Treatment with an investigational medicinal product that is not expected to be cleared by the first dose of study drug or that has demonstrated to have prolonged side effects. * Treatment with azacitidine or decitabine within 2 weeks prior to first dose of study drug. * Chronic use (\> 2 weeks) of greater than physiologic doses of corticosteroids (dose equivalent to \> 20 mg/day of prednisone) within 4 weeks prior to first dose of study drug. * Treatment with an immunomodulatory agent within 4 weeks prior to the first dose of study drug. * Additional criteria exist.